Rucaparib As Maintenance Therapy Delays Progression in Patients with Platinum-Sensitive Recurrent Ovarian Cancer
Results from the phase 3 ARIEL3 clinical trial showed that maintenance therapy with rucaparib leads to significantly improved progression-free survival in patients with advanced ovarian cancer and non-BRCA homologous recombinant repair gene mutations.
Niraparib plus Bevacizumab Combination Leads to Improved PFS Without Cumulative Toxicity in Advanced Ovarian Cancer
At the 12-month landmark analysis of the single-arm phase 2 OVARIO clinical trial, 75% of patients in the overall population of patients with newly diagnosed stage IIIB-IV ovarian cancer remained progression-free.
Adding Olaparib to Bevacizumab as Maintenance Extends PFS in Newly Diagnosed Advanced Ovarian Cancer
Data from the phase 3 PAOLO-1 clinical trial showed that progression-free survival was significantly increased with olaparib plus bevacizumab as maintenance therapy.
PARP Inhibitors in Ovarian Cancer: Choice May Depend on Treatment Setting, Mutation Status, and Side-Effect Profile
The approval of 3 PARP inhibitors has made it feasible to personalize therapy for patients with ovarian cancer based on their mutation status as well as other factors, including the treatment setting.
Time to First Subsequent Therapy Longer in Patients with Advanced Ovarian Cancer Who Are Treated with Niraparib
The phase 3 PRIMA clinical trial demonstrated that time to first subsequent therapy was 6.6 months longer in the niraparib arm versus the placebo arm, an advantage that was maintained regardless of homologous recombination deficiency status, and the risk for second disease progression was also numerically lower in niraparib-treated patients.
Improvement in progression-free survival observed in the PRIMA clinical trial results in FDA approval of an additional indication for niraparib as first-line maintenance treatment of all patients with advanced ovarian cancer whose disease has had a complete or partial response to first-line platinum-based chemotherapy.
In this exclusive interview, Melissa Paige, Chief Executive Officer and Founder, Paige Consulting, LLC, Charlottesville, VA, and Infusion/Oncology Patient Access Principal Coordinator at a large academic center, shares her experience in helping patients with cancer obtain access to oral and infused therapies.
The Centers for Medicare & Medicaid Services (CMS) has announced an expansion of coverage for telehealth services for Medicare beneficiaries. To qualify, 2-way real-time interactive communication between providers and patients using both audio and video technology is required.
Remote patient monitoring, in which digital technologies are used to detect changes in vital signs or symptoms, may offer a convenient way to signal the need for a change in management, thereby potentially improving outcomes.
According to data from the National Cancer Institute, approximately 1.2% of women in the United States will be diagnosed with ovarian cancer at some point in their lifetime. It is estimated that more than 20,000 women will be diagnosed with ovarian cancer in 2020, and nearly 14,000 women will die from the disease in the same year. Most deaths will occur in women aged >55 years.
Page 1 of 4
Results 1 - 10 of 37
Results 1 - 10 of 37